Targeted Alpha Therapy Using Components of the Plasminogen Activation System for the Control of Micrometastatic Breast Cancer
Abstract
The major failure in breast cancer management is the incomplete killing of malignant tumour cells that have spread throughout the body 1. This is despite the many treatments available, such as surgery, radiation therapy, hormone therapy and chemotherapy. The American Cancer Society estimated 182,800 new cases of invasive breast cancer in the year 2000 among women in America, and 40,800 are expected to die from the disease 2. Novel, more effective treatments that overcome this problem in breast cancer management are essential. Targeted therapy, first discussed over 100 years ago, is based on the idea that a drug will attack its target without damaging other tissue 3. Targeted alpha therapy (TAT) uses an alpha emitting radionuclide as a lethal medicament via an effective targeting carrier to kill cancer cells 5. We are investigating a novel TAT approach that exploits the involvement of cell-surface receptor bound urokinase plasminogen activator (uPA) in the metastatic spread of breast cancer cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2001
- Accession Number
- ADB277418
Entities
People
- Barry J. Allen
- Marie Ranson